Summary
The consumption of antidiabetic drugs in a Spanish region (Extremadura) in the period 1986–1987 has been investigated by the “defined daily dose” (DDD) method.
The study was done in three health care systems in the region: civil servants (“Mutualidad de Funcionarios Civiles del Estado: MUFACE”) armed forces group (“Instituto Social de las Fuerzas Armadas: ISFAS”) and the national system (“Instituto Nacional de la Salud: INSALUD”). The total consumption of antidiabetic drugs varied three-fold, ranging from 5,73 DDD per 1000 inhabitants per day (3,71 DDD per 1000 inhabitants per day for oral antidiabetic drugs and 2,02 DDD per 1000 inhabitants per day for insulin) in the civil servant group to 15,82 DDD per 1000 inhabitants per day (12 DDD per 1000 inhabitants per day for oral antidiabetic drugs and 3,82 DDD per 1000 inhabitants per day for insulins) in the armed forces. The differences were more pronounced for oral antidiabetics than for insulins. The utilization of insulin among the civil servants was about half of that by the two other groups. Of oral antidiabetics, sulphonylureas were the most frequently used by the three groups, and within them glibenclamide accounted for more than half of the DDDs, while biguanides were scarcely used in any group. The differences are difficult to assess, since they could be due to several factors, such as age-differences in the population studied, different prescribing habits, and differences in sociocultural level. The results justify further comparative studies of drug utilization in different health systems within the same region.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Engel A, Siderius P (1968) The consumption of drugs: Report on a study 1966–1967. Euro 3101. WHO Regional Office for Europe, Copenhagen
Grímsson A (1980) Drug utilization research. Pharm Int 1245–1247
Lunde PKM, Baksaas I, Halse M, Halvorsen IK, Stromnes, Oydvin K (1979) The methodology of drug utilization studies. In: Bergman U, Wahba AHW, Grímsson A, Westerholm B (eds.), Studies in drug utilization. Methods and applications. European Series No. 8. WHO Regional Office for Europe, Copenhagen, pp 17–28
Bergman U, Sjöqvist F (1982) Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Med Scand 683 [Suppl]: 15–22
Baksaas I (1982) Patterns in drug utilization-National and international aspects: Antihypertensive drugs. Acta Med Scand 683 [Suppl]: 59–66
King DJ, Griffiths K (1982) Patterns in drug utilization-national and international aspects: Psychoactive drugs 1966–80. Acta Med Scand 683 [Suppl]: 71–77
WHO Drug Utilization Research Group (DURG) (1986) Therapeutic traditions in Northern Ireland, Norway and Sweden: II Hypertension. Eur J Clin Pharmacol 30: 521–525
Nordic Council on Medicines, Nordic Statistics on Medicines 1981–1983 (1986) NLN Publications No 14–16, Uppsala, Sweden
Griffiths K, McDevitt DG (1983) A Community Pharmacy-based survey of antihypertensive and antidiabetic drug dosages in Northern Ireland. J Clin Hosp Pharm 8: 115–124
Bergman U, Elmes P, Halse M, Halvorsen T, Hood M, Lunde PKM, Sjöqvist F, Wade OL, Westerholm B (1975) The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway, and Sweden. Eur J Clin Pharmacol 8: 83–89
Bergman U (1978) Utilization of antidiabetic drugs in the Island of Gotland, Sweden: Agreement between wholesale figures and prescription data. Eur J Clin Pharmacol 14: 213–220
Bergman U (1979) International comparisons of drug utilization: Use of antidiabetic drugs in seven European countries. In: Bergman U, Wahba AHW, Grímsson A, Westerholm B (eds): Studies in drug utilization. Methods and applications. European Series No 8. WHO Regional Office for Europe, Copenhagen, 147–162
Stanulovic M, Jakovljevic V, Kovac T, Lepsanovic L and Ducic M (1986) Regional and international comparison in utilization of antidiabetic drugs. Int J Clin Ther Toxicol 24: 254–256
Andrew M (1984) Utilization of antidiabetic drugs in the Nordic Countries. Acta Endocrinol [Suppl] 262: 113–117
Stika L (1984) Patterns in Drug utilization-national and international aspects: antidiabetic drugs. Acta Med Scand [Suppl] 683: 53–57
WHO Drug Utilization Research Group (DURG) (1985) Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 30: 521–525
Pagés MT, Recalde JM, Arias A (1987) Utilización de medicamentos antidiabéticos en Andalucia y España en 1984–1985. Farm Clin 4: 651–658
Barbeira Barja JM, Levy Mahfoda M, García Iñesta I (1983) Consumo de medicamentos antidiabéticos. Uso relativo de antidiabéticos orales respecto a insulina. InfTer Segur Soc 7: 112–118
WHO Drug Utilization Research Group (DURG) (1986) Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. Eur J Clin Pharmacol 30: 513–519
Stalhammar J, Bergman U, Boman K, Dahlén M. Metabolic control in diabetic patients in three Swedish areas with high, medium and low sales of antidiabetic drugs. Diabetes Care (in press)
Taboulet F (1991) Comparative consumption of antidiabetic drugs in Britain, France and Germany. Eur J Clin Pharmacol 40: 303–304
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benítez, J., Puerto, A.M. & Díaz, J.A. Differences in antidiabetic drug utilisation between three different health systems in the same national region. Eur J Clin Pharmacol 42, 151–154 (1992). https://doi.org/10.1007/BF00278475
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278475